News | March 31, 2021
Investment opportunities in India’s healthcare sector: NITI Aayog
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
The vaccine was 85 percent effective in preventing severe disease across all regions.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
Candid Powder brand is a market-leader in its category, with a market share of 64% in the medicated powder category.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Subscribe To Our Newsletter & Stay Updated
